Drug intelligence / Profile preview

7e

Development stage: Preclinical
Modality: Small Molecules
Administration: Intragastric

Overview

7e is a novel flavanone derivative with potential antipsychotic effects. It has been shown to decrease the activity of dopamine D2 receptors in HEK293 cells and inhibit the over-production of nitric oxide stimulated by lipopolysaccharide/interferon-γ in BV-2 microglial cells. In mice, intragastric administration of 7e reversed the increase in locomotor activity induced by MK-801 and decreased the hyperactivity of climbing behavior induced by apomorphine, suggesting its potential utility in the treatment of schizophrenia.

Targets

DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on 7e.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 7e.

Explore the full profile